8 November, 2023

FDA’s New Guidance on Biosimilar Labeling: A Step Towards Clarity and Confidence

Did you know both biosimilars and interchangeable biosimilars adhere to the same stringent FDA standards, ensuring their efficacy and safety?

The FDA now recommends a unified “Biosimilarity Statement” in labeling, streamlining communication and eliminating confusion among healthcare providers. This change aligns with the FDA’s accumulated experience and ensures a focus on crucial scientific information.

Download Here

Discover how we can help you

Close Popup

This site uses cookies to personalise and customise your experience. By clicking “I Accept", you consent to cookies in accordance with our privacy policy.

Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Cloudflare
In order to use this website we use the following technically required cookies
  • __cfduid

Decline all Services
Save
Accept all Services